Lymerix recombinant outer-surface lipoprotein A: Phase III data; awaiting approval

SmithKline Beecham published in The New England Journal of Medicine results of a 10,936-patient Phase III trial of its Lymerix Lyme disease vaccine.

In the first year, after two injections, 22 patients in the vaccine group and 43 in the placebo group contracted Lyme disease (p=0.009), for a vaccine efficacy of 49 percent. In the second year, after the third injection, 16 vaccine recipients and 66 placebo recipients contracted Lyme disease (p<0.001) for a vaccine efficacy of 76 percent. Side effects included mild-to-moderate local or systemic reactions lasting a median of 3 days. ...